
Nanosphere Inc (AKA: Nanosphere LLC) Profile last edited on: 4/26/2019
CAGE: 1ZDW3
UEI: DNQ4H6RCTMJ5
Business Identifier: Molecular diagnostics: simplified molecular testing based on nanoparticles of gold Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 10
County: Cook
Congr. District: 10
County: Cook
Public Profile
In May 2016, Nanosphere was acquired by Luminex Corporation itself and SBIR -involved firm - in a cash deal reported as $77M also to include retiring $25M of Nanosphere's debt. Nanosphere, Inc. had been organized around a molecular diagnostics platform -- Verigene System -- that enabled genomic and protein testing on a single platform. The firm's proprietary nanoparticle technology provided the ability to run multiple tests simultaneously on the same sample, as well as simplifies molecular diagnostic testing. The company developed diagnostic tests for markers, which reveal the existence of various medical conditions, including cardiovascular, respiratory, cancer, autoimmune, neurodegenerative, and other infectious diseases, as well as for pharmacogenomics. It also engaged in developing and commercializing genomic and protein assays, including hyper-coagulation, warfarin metabolism, cystic fibrosis, respiratory virus panel, hemochromatosis, blood infection panel, cardiac troponin I, connective tissue, prostate specific antigen, and biomarker validation.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
150-249Revenue Range
15M-20MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : NSPHIP Holdings
50-74Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2007 | 1 | NIH | $291,293 | |
Project Title: A Novel Diagnostic Test for Clostridium difficile-Associated Diarrhea (CDAD) | ||||
2006 | 1 | Army | $100,000 | |
Project Title: Colorimetric Sensors for Chemical and Biological Warfare Agents | ||||
2005 | 2 | NIH | $849,800 | |
Project Title: Nanoparticle Probe Assay for Biological Threat Agents | ||||
2003 | 2 | NIH | $867,800 | |
Project Title: Rapid Assay for the I1307k Mutation of the APC Gene | ||||
2003 | 2 | NIH | $866,198 | |
Project Title: An Assay for Genetic Mutations Causing Hypercoagulation |
Key People / Management
William Moffitt -- President and Chief Executive Officer
Bill Athenson -- Vice President, Business Development
William H Cork -- Chief Technology Officer
Winton G Gibbons -- Senior Vice President of Business Development
Eva J Gordon
Michael McGarrity -- Chief Marketing Officer
Chad A Mirkin -- Former President
Roger Moody -- Vice President of Finance, Treasurer and Chief Financial Officer
Tim Patno -- Vice President, Technology
Greg Shipp -- Vice President, Medical Affairs
James J Storhoff
Stephen Wasko -- Chief Financial Officer
Bill Athenson -- Vice President, Business Development
William H Cork -- Chief Technology Officer
Winton G Gibbons -- Senior Vice President of Business Development
Eva J Gordon
Michael McGarrity -- Chief Marketing Officer
Chad A Mirkin -- Former President
Roger Moody -- Vice President of Finance, Treasurer and Chief Financial Officer
Tim Patno -- Vice President, Technology
Greg Shipp -- Vice President, Medical Affairs
James J Storhoff
Stephen Wasko -- Chief Financial Officer
Company News
There are no news available.